How a UK VC Scaled China’s Healthcare Startups via Onshore Fund: Case Study
In 2020, a top-tier UK venture capital firm deployed a ¥1.2 billion (RMB fund, rénmínbì jījīn) onshore fund dedicated exclusively to China’s healthcare startups. Within four years, the fund achieved a 3.2x gross multiple, backed three unicorns, and facilitated two IPOs on the Hong Kong Stock Exchange (HKEX) and Shanghai’s STAR Market. This case study examines how the firm navigated China’s regulatory and operational complexities to scale high-potential healthcare companies through an onshore structure, bypassing the traditional offshore (外商投资企业, WFOE, wàishāng dúzī qǐyè) model.
Background: The UK VC’s China Challenge
The UK firm, with £8 billion in assets under management, had invested in China via offshore WFOE structures since 2015. However, by 2018, two challenges emerged: first, regulatory changes restricted offshore capital from accessing strategic healthcare sectors—including gene therapy, medical devices, and digital health—under China’s Negative List for foreign investment. Second, portfolio companies founded by Chinese nationals preferred RMB-denominated funding to avoid currency risk and expedite regulatory approvals for clinical trials and product registrations.
In 2019, the firm established a wholly foreign-owned enterprise (外商独资企业, WFOE, wàishāng dúzī qǐyè) in Shanghai, but the WFOE could only invest in a limited subset of healthcare subsectors. To scale, they needed a qualified foreign limited partnership (合格境外有限合伙人, QFLP, hégé jìngwài yǒuxiàn héhuǒrén) structure—a pilot program allowing foreign capital to be converted into RMB for domestic equity investments.
Between 2019 and 2020, the firm spent ¥12 million on legal, compliance, and licensing costs to secure a QFLP license from the Shanghai Financial Regulatory Bureau. They raised ¥1.2 billion from three anchor LPs: a UK pension fund (¥500 million), a Middle Eastern sovereign wealth fund (¥400 million), and a Hong Kong family office (¥300 million). The capital was committed in RMB, with a 10-year fund life—significantly longer than the typical 7-8 years for offshore funds—to accommodate the longer R&D and regulatory cycles in healthcare.
Building the Onshore Fund: Structure & Strategy
The fund operated as a QFLP with a parallel Cayman vehicle. The Cayman entity held the offshore LP commitments, while the Shanghai-based QFLP converted foreign currency into RMB via a special cross-border quota approved by the State Administration of Foreign Exchange (SAFE). Each capital call required a 15-day conversion window, with a 0.3% FX cost per transaction—versus 0.1% for a standard offshore USD fund.
The firm’s investment thesis focused on three healthcare sub-segments: AI diagnostics (e.g., imaging software), regenerative medicine (stem cell therapies), and home-based chronic care devices. They targeted companies with regulatory filings with the National Medical Products Administration (NMPA) that had already achieved Class II or Class III certification, reducing de-risking time.
Table: Offshore Fund vs. Onshore QFLP Fund for China Healthcare VC
| Parameter | Offshore Fund (WFOE / BVI) | Onshore QFLP Fund (this case) |
|---|---|---|
| Regulatory approval time | 4-6 months (NMPA review if healthcare) | 12-18 months (QFLP license + quota application) |
| Capital conversion cost | 1.5-2.5% (offshore-to-RMB via VIE) | 0.3% per call (direct FX conversion) |
| Investment scope | Restricted; excludes genetics, AI diagnostics, stem cells | Full; includes regulated healthcare sectors |
| Exit channels | Offshore IPO (HKEX, Nasdaq); VIE structure required | Onshore IPO (STAR, ChiNext, HKEX) via clean structure |
| LP domicile preference | Sovereign wealth, US/UK pension funds | China-friendly LPs; RMB-as-base preferred |
| Fund life | 7-8 years | 10 years (standard for QFLP) |
| Carry distribution | 20% carried interest, payable in USD | 20% carried interest, payable in RMB (with FX conversion allowed) |
Decision Framework: If your LPs require RMB exposure without currency mismatch risk for domestic IPO exits, choose the QFLP onshore structure. If your LPs are strictly USD-based with a preference for offshore liquidity events (Nasdaq, SEHK), choose the offshore WFOE or VIE structure. In this case, the UK firm’s LPs were comfortable with RMB repatriation timelines of 60-90 days post-exit, making the onshore fund the right fit.
Portfolio Performance: Scaling China’s Healthcare Ecosystem
Between Q1 2021 and Q4 2023, the fund made 12 investments—6 in AI diagnostics, 4 in regenerative medicine, and 2 in chronic care devices. Total deployed capital: ¥1.05 billion (87.5% of fund). The remaining ¥150 million was reserved for follow-on rounds and operational buffers.
Three key outcomes:
- Unicorn 1 (AI diagnostics): Backed at ¥500 million valuation in 2021; reached ¥8 billion post-money in 2024 after receiving NMPA Class III certification for lung cancer detection. The fund realized a 4.1x gain via secondary stake sale.
- Unicorn 2 (regenerative medicine): Developed an off-the-shelf stem cell therapy for osteoarthritis. Raised a Series C led by a Chinese state-owned PE fund (¥300 million). Fund’s cost basis: ¥120 million; current valuation: ¥1.5 billion.
- IPO (chronic care device): Listed on STAR Market in September 2024 with an opening market cap of ¥6.8 billion. Fund exited 40% of holding, returning ¥320 million to LPs—a 2.1x return in 3 years.
The overall fund IRR stood at 27.4% as of 2025 Q1, compared to the benchmark China healthcare VC index of 18.1% over the same period. Notably, 83% of portfolio companies received subsequent funding from Chinese domestic VCs, validating the onshore fund’s deal access and reputation-building within the local ecosystem.
Three Critical Pitfalls (and How They Were Overcome)
Lessons for Foreign VC in China Healthcare
This case demonstrates that an onshore QFLP fund is not merely a compliance workaround—it is a strategic choice that unlocks access to China’s most regulated and high-growth healthcare subsectors. The UK firm’s success hinged on three decisions: first, committing to a 10-year fund life that matched healthcare R&D timelines; second, hiring local regulatory talent with direct relationships at NMPA and SAFE; and third, accepting the 0.3% FX cost as a premium for direct investment access.
For foreign VC considering onshore structures, the key trade-off is regulatory patience vs. investment return. The QFLP setup cost ¥12 million and took 18 months, but it yielded access to deals that would have been impossible via offshore vehicles. In this case, the fund’s 27.4% IRR and 3.2x gross multiple justify the upfront complexity.
NEXT STEPS
- Assess your fund’s LP profile: If your LPs can accept RMB-denominated returns and 10-year lock-ups, explore the QFLP license application process for healthcare focus. Consult our guide on China healthcare foreign investment restrictions to confirm your subsectors are eligible.
- Build a local regulatory team: Allocate ¥1.5–2 million for a compliance advisor with NMPA and SAFE experience. Our regulatory compliance checklist for healthcare startups outlines the key approvals needed pre-investment.
- Plan exit structures early: Before deploying capital, decide whether you will repatriate via onshore IPO (STAR/ChiNext) or offshore SPV. Use our exit strategy comparison for China VC funds to evaluate pros and cons.
— China Gateway 360 —
Remote China market entry support, built around execution.
